Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products. These products are used in various applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care, and as non-toxic disinfectants. The company's products are clinically proven to safely reduce itch, pain, scarring, and irritation without damaging healthy tissue. In-vitro and clinical studies indicate HOCl can safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma Pharmaceuticals sells its products directly or through partners in over 55 countries worldwide. The company has two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Its fiscal year ends on March 31. Recently, the company successfully transitioned all of its commercialized products in Europe, including eye care, wound care, scar gel, acne products, and atopic dermatitis products, to the new European Union (EU) Medical Device Regulation (MDR).